# Johnson Controls International (JCI) – Q4 2025 Earnings Summary

**Earnings Date:** November 2025  
**Fiscal Year End:** September 30, 2025  
**Reporting Period:** Q4 FY2025 (July-September 2025)

---

## Earnings Results

### Key Metrics vs. Estimates

| Metric | Actual | Estimate | Beat/Miss | Variance |
|--------|--------|----------|-----------|----------|
| **Adj EPS** | $1.26 | $1.20 | ✅ **BEAT** | +5.0% |
| **GAAP EPS** | $0.42 | $1.21 | ❌ **MISS** | -65.3% |
| **Revenue** | $6.44B | $6.33B | ✅ **BEAT** | +1.7% |

### 2026 Guidance vs. Estimates

| Metric | Guidance | Estimate | Variance |
|--------|----------|----------|----------|
| **2026 Adj EPS** | ~$4.55 | $4.43 | ✅ **BEAT** (+2.7%) |
| **Q1 2026 Adj EPS** | ~$0.83 | $0.82 | ✅ **BEAT** (+1.2%) |

---

## Analysis

### Q4 2025 Results

**Mixed Results - Adjusted Beats, GAAP Misses:**
- ✅ **Adj EPS Beat:** $1.26 exceeded estimates by $0.06 (+5.0%)
- ✅ **Revenue Beat:** $6.44B exceeded estimates by $110M (+1.7%)
- ❌ **GAAP EPS Miss:** $0.42 missed by $0.79 (-65.3%) - significant miss

**Key Observation:**
- Large gap between GAAP ($0.42) and Adjusted ($1.26) EPS suggests significant one-time charges
- Adjusted EPS beat indicates underlying operational performance exceeded expectations
- GAAP miss likely due to restructuring charges, portfolio actions, or other identified items

### 2026 Guidance - Positive

**2026 Adjusted EPS Guidance: ~$4.55**
- **Expected:** $4.43
- **Variance:** +$0.12 (+2.7%)
- **Interpretation:** Guidance ahead of expectations, indicating:
  - Management confidence in operational improvement
  - Lean transformation initiatives showing traction
  - Portfolio optimization benefits materializing
  - Margin expansion expectations

**Q1 2026 Guidance: ~$0.83**
- **Expected:** $0.82
- **Variance:** +$0.01 (+1.2%)
- **Interpretation:** Solid start to fiscal year expected

### Key Takeaways

**Positive:**
1. **Adj EPS Beat:** Operational performance exceeded expectations (+5%)
2. **Revenue Beat:** Top-line growth ahead of estimates
3. **Guidance Above Expectations:** 2026 guidance +2.7% above estimates
4. **Operational Improvement:** Lean transformation and portfolio actions showing results

**Concerns:**
1. **GAAP EPS Miss:** Large gap between GAAP and Adjusted suggests significant charges
2. **One-Time Items:** Need clarity on nature of charges affecting GAAP EPS
3. **Consistency:** Need to monitor if adjusted metrics reflect true operational performance

---

## Market Impact Assessment

**Likely Positive Near-Term:**
- Stock likely to react positively to adjusted EPS beat and guidance raise
- Guidance ahead of expectations indicates management confidence
- Operational improvements validating transformation thesis

**Investment Thesis Impact:**
- **Short-term:** Positive - Adjusted metrics beat expectations
- **Medium-term:** Positive - Guidance raise supports thesis
- **Long-term:** Thesis intact - Transformation initiatives showing progress

---

## Investment Implications

### Prior Thesis (from consolidated ranking):
- **Score:** 72/100 ❌ **Not Selected**
- **Recommendation:** Hold/Buy for patient investors
- **Key Risks:** Transformation execution risk, premium valuation, negative working capital

### Post-Earnings Assessment:

**Risk Factors Improved:**
- Guidance ahead of expectations indicates execution success
- Operational improvement validating lean transformation
- Portfolio optimization benefits materializing

**Remaining Concerns:**
- GAAP EPS miss requires explanation (one-time charges)
- Premium valuation still a consideration
- Negative working capital still a concern
- Need consistent execution over multiple quarters

**Revised Outlook:**
- Near-term: **POSITIVE** - Adjusted metrics beat, guidance raised
- Medium-term: **CAUTIOUSLY OPTIMISTIC** - Transformation showing progress
- Long-term: **THESIS INTACT** - But requires continued execution

---

## Key Questions for Management

1. **GAAP vs. Adjusted Gap:** What drove the large GAAP EPS miss ($0.42 vs. $1.26)?
2. **One-Time Charges:** What restructuring or portfolio actions impacted GAAP results?
3. **Guidance Confidence:** What drives confidence in 2026 guidance above expectations?
4. **Lean Transformation:** How much of the guidance raise is from lean initiatives?
5. **Portfolio Actions:** Are portfolio optimization benefits included in guidance?

---

## Comparison to EMR (Also Reported Q4)

**JCI vs. EMR Q4 Results:**
- **JCI:** Adj EPS beat (+5%), guidance raised (+2.7%)
- **EMR:** Adj EPS miss (-13%), guidance cut significantly (-318 bps)
- **JCI:** Operational improvement validating transformation
- **EMR:** Operational deterioration requiring reset

**Investment Implications:**
- JCI showing execution success vs. EMR execution challenges
- JCI guidance raise vs. EMR guidance cut
- JCI validating transformation thesis vs. EMR requiring reassessment

---

*Earnings summary created: November 2025*  
*Source: Earnings release, analyst estimates*
